BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Obesity
,
Lymphocyte
,
Alcohol
,
Lipitor
,
rs7903146
,
LEP
,
Fatty acid metabolic process
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
CP 2
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Low ceruloplasmin levels exacerbate retinal degeneration in a hereditary hemochromatosis model.
Targeting hepatic ceruloplasmin mitigates nonalcoholic steatohepatitis by modulating bile acid metab…
Disruption of Dcp1 leads to a Dcp2-dependent aberrant ribosome profiles in Aspergillus nidulans.
Tumor associated macrophages transfer ceruloplasmin mRNA to fibrosarcoma cells and protect them from…
Ceruloplasmin regulating fibrosis in orbital fibroblasts provides a novel therapeutic target for Gra…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory S…
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus …
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Estimation of Effective Dose 95 (ED95) of Intrathecal Isobaric 2-chloroprocaine (2-CP) Based on the …
Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ